可切除肝细胞癌的辅助和新辅助治疗。
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.
机构信息
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E Duarte Road, Duarte, CA, 91010, USA.
出版信息
Curr Oncol Rep. 2023 Oct;25(10):1191-1201. doi: 10.1007/s11912-023-01455-9. Epub 2023 Sep 9.
Abstract
PURPOSE OF REVIEW
This review provides an update on the developments of adjuvant and neoadjuvant liver-directed and systemic therapy options for patients with resectable hepatocellular carcinoma.
RECENT FINDINGS
Data on liver-directed treatment in the adjuvant and neoadjuvant settings are sparse and results are conflicting; many studies suggest that optimizing patient selection criteria is a key milestone required to improve study design and clinical benefit to patients. Systemic treatment options are primarily focused on investigation of anti-PD-1/L1 immunotherapeutic agents, either alone or in combination with other drugs. Numerous clinical trials in both adjuvant and neoadjuvant settings are in progress. Exploration of liver-directed and systemic treatment options for adjuvant and neoadjuvant treatment of patients with resectable hepatocellular carcinoma has the potential to improve clinical outcomes for this patient population.
摘要
目的综述
本文就可切除肝细胞癌患者的辅助和新辅助肝靶向和系统治疗选择的进展进行综述。
最近的发现
辅助和新辅助肝靶向治疗的数据有限且结果相互矛盾；许多研究表明，优化患者选择标准是提高研究设计和临床获益的关键里程碑。系统治疗方案主要侧重于研究抗 PD-1/L1 免疫治疗药物，单独或联合其他药物。目前正在进行许多辅助和新辅助环境中的临床试验。探索可切除肝细胞癌患者辅助和新辅助治疗的肝靶向和系统治疗选择，有可能改善该患者人群的临床结局。
相似文献
1
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.可切除肝细胞癌的辅助和新辅助治疗。
Curr Oncol Rep. 2023 Oct;25(10):1191-1201. doi: 10.1007/s11912-023-01455-9. Epub 2023 Sep 9.
2
Hepatocellular carcinoma systemic treatment update: From early to advanced stage.肝细胞癌全身治疗进展：从早期到晚期
Biomed J. 2024 Nov 17:100815. doi: 10.1016/j.bj.2024.100815.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.肝细胞癌手术切除的新辅助和辅助治疗。
Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD001199. doi: 10.1002/14651858.CD001199.pub2.
5
The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review.新辅助/辅助/化学预防治疗在肝细胞癌肝部分切除术中的当前作用：一项系统评价
Hepatobiliary Pancreat Dis Int. 2009 Apr;8(2):124-33.
6
Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.新辅助免疫检查点抑制剂治疗肝细胞癌：荟萃分析和系统评价。
Front Immunol. 2024 Feb 19;15:1352873. doi: 10.3389/fimmu.2024.1352873. eCollection 2024.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.针对接受根治性手术的直肠癌患者的术后辅助化疗。
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2.
9
Potential of neoadjuvant hepatic artery perfusion chemotherapy in improving surgical outcomes in hepatocellular carcinoma: a systematic review and meta-analysis.新辅助肝动脉灌注化疗改善肝细胞癌手术疗效的潜力：一项系统评价与荟萃分析
World J Surg Oncol. 2025 May 29;23(1):207. doi: 10.1186/s12957-025-03859-2.
10
Immune checkpoint blockade and transarterial chemoembolization in liver-limited hepatocellular carcinoma: new questions at the dawn of a new era.免疫检查点阻断与经动脉化疗栓塞术治疗肝局限性肝细胞癌：新时代伊始的新问题
J Immunother Cancer. 2025 Aug 27;13(8):e012658. doi: 10.1136/jitc-2025-012658.
引用本文的文献
1
Prophylactic transarterial chemoembolization after R0 resection is beneficial to improve the prognosis in hepatocellular carcinoma patients with microvascular invasion.R0切除术后预防性经动脉化疗栓塞术有利于改善伴有微血管侵犯的肝细胞癌患者的预后。
Discov Oncol. 2025 Jun 3;16(1):995. doi: 10.1007/s12672-025-02722-w.
2
METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery.METTL1驱动的核苷酸代谢重编程肝细胞癌的免疫微环境：一种用于发现预后生物标志物的多组学方法
Front Immunol. 2025 Apr 22;16:1582203. doi: 10.3389/fimmu.2025.1582203. eCollection 2025.
3
Prognostic significance of the liver stiffness value on magnetic resonance imaging elastography in patients undergoing hepatectomy for hepatocellular carcinoma.肝细胞癌肝切除患者磁共振弹性成像中肝脏硬度值的预后意义
Surg Today. 2025 Apr 3. doi: 10.1007/s00595-025-03034-w.
本文引用的文献
1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.卡瑞利珠单抗联合瑞戈非尼对比索拉非尼作为不可切除肝细胞癌一线治疗（CARES-310）：一项随机、开放标签、国际多中心 3 期研究。
Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.
3
Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy.辅助性经动脉化疗栓塞术可能无法改善肝切除术后复发风险较低的肝癌患者的无复发生存期或总生存期。
Front Oncol. 2023 May 24;13:1104492. doi: 10.3389/fonc.2023.1104492. eCollection 2023.
4
Adjuvant and neoadjuvant approaches in pancreatic cancer.胰腺癌的辅助和新辅助治疗方法。
Curr Opin Oncol. 2023 Jul 1;35(4):326-333. doi: 10.1097/CCO.0000000000000962. Epub 2023 May 12.
5
Role of CD147 in the development and diagnosis of hepatocellular carcinoma.CD147 在肝细胞癌发生发展及诊断中的作用。
Front Immunol. 2023 Apr 6;14:1149931. doi: 10.3389/fimmu.2023.1149931. eCollection 2023.
6
Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.辅助 TACE 对肝癌患者肝切除术后预后的疗效：来自中国的多中心倾向评分匹配研究。
BMC Cancer. 2023 Apr 7;23(1):325. doi: 10.1186/s12885-023-10802-9.
7
Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A/B hepatocellular carcinoma beyond Milan criteria: A randomized clinical trial.肝切除术与经动脉化疗栓塞术治疗超出米兰标准的可切除BCLC A/B期肝细胞癌：一项随机临床试验
Front Oncol. 2023 Feb 27;13:1101162. doi: 10.3389/fonc.2023.1101162. eCollection 2023.
8
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.可切除结肠癌的术前化疗：一项国际随机对照试验的成熟结果。
J Clin Oncol. 2023 Mar 10;41(8):1541-1552. doi: 10.1200/JCO.22.00046. Epub 2023 Jan 19.
9
Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): Multicenter retrospective study.术前经导管动脉化疗栓塞术治疗单发大肝癌（≥5cm）患者的预后：多中心回顾性研究。
Cancer Med. 2023 Apr;12(7):7734-7747. doi: 10.1002/cam4.5529. Epub 2022 Dec 20.
10
Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study.仑伐替尼联合抗PD-1抗体加经动脉化疗栓塞术用于新辅助治疗具有高复发风险的可切除肝细胞癌：一项多中心回顾性研究
Front Oncol. 2022 Sep 21;12:985380. doi: 10.3389/fonc.2022.985380. eCollection 2022.
Zotero 插件